Bio-Connect
Immunocytochemistry fluorescent staining of human mature dendritic cells using anti-IDO (human), pAb (Prod. No. AG-25A-0029).
Immunocytochemistry fluorescent staining of human mature dendritic cells using anti-IDO (human), pAb (Prod. No. AG-25A-0029).
Immunocytochemistry fluorescent staining of human mature dendritic cells using anti-IDO (human), pAb (Prod. No. AG-25A-0029).

anti-IDO1 (human), pAb

Research Use Only
AG-25A-0029
AdipoGen Life Sciences
ApplicationsFlow Cytometry, Western Blot, ELISA, ImmunoCytoChemistry
Product group Antibodies
ReactivityHuman
TargetIDO1
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    anti-IDO (human), pAb
  • Delivery Days Customer
    10
  • Antibody Specificity
    Recognizes human IDO1. Detects a band of ~45kDa by Western blot.
  • Applications
    Flow Cytometry, Western Blot, ELISA, ImmunoCytoChemistry
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    1 mg/ml
  • Formulation
    Liquid
  • Gene ID3620
  • Target name
    IDO1
  • Target description
    indoleamine 2,3-dioxygenase 1
  • Target synonyms
    IDO; IDO-1; INDO; indolamine 2,3 dioxygenase; indole 2,3-dioxygenase; indoleamine 2,3-dioxygenase 1; indoleamine-pyrrole 2,3-dioxygenase
  • Host
    Rabbit
  • Protein IDP14902
  • Protein Name
    Indoleamine 2,3-dioxygenase 1
  • Scientific Description
    IDO1 is a heme enzyme that catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway, causing depletion of tryptophan which can lead to halted growth of microbes as well as T cells. IDO1 is an immune checkpoint protein, thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation and antioxidant activity. Cancer cells are able to evade the immune system is by hijacking the checkpoint proteins. Increased IDO1 protein levels drive growth arrest and apoptosis of the effector T cells, a group of immune cells that mediate the immune systems ability to destroy pathogens. By reducing the number of effector T cells, IDO1 overexpression prevents the immune system from effectively destroying cancer cells. IDO1 overexpression has been observed in a wide range of human cancers such as prostatic, colorectal, pancreatic, cervical, gastric, ovarian, head or lung cancer. Physiological IDO1 activity has been implicated in T cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders. - Polyclonal Antibody. Recognizes human IDO. Detects a band of ~45kDa by Western blot. Source: Rabbit. Applications: ELISA, FACS, ICC, WB. Liquid. 0.2microm-filtered solution in PBS, pH 7.4. Contains no preservatives. IDO catalyzes the first and rate-limiting step in the main pathway of human tryptophan catabolism, the kynurenine pathway. Proinflammatory mediators, such as endotoxin and IFN-gamma induce the expression of IDO in several tissues. IDO-dependent suppression of T-cell responses might function as natural immunoregulatory mechanism. Physiological IDO activity has been implicated in T-cell tolerance to tumors, dysfunctional selftolerance in non-obese diabetic (NOD) mice, and as a protective negative regulator in autoimmune disorders.
  • Reactivity
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352203